

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
 Art Unit: _____ Phone Number 301-____-____ Serial Number: _____
 Mail Box and Bldg Room Location: _____ Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

STAFF USE ONLY**Type of Search****Vendors and cost where applicable**

Searcher _____

NA Sequence (#) _____

STN _____

Searcher Phone # _____

AA Sequence (#) _____

Dialog _____

Searcher Location _____

Structure (#) _____


Questel Orbit _____

www. _____

Online Time _____

Other _____

Other (specify) _____



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed for

Go Clear

Limits Preview/Index History Clipboard Details

Display

Abstract

Show: 20

Sort

Send to

Text

1: Nature 1985 Mar 28-Apr 3;314(6009):374-7

Related Articles, Links

Entrez PubMed

An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins.

Pellman D, Garber EA, Cross FR, Hanafusa H.

PubMed
Services

The src gene product, p60src, of Rous sarcoma virus (RSV) is a tyrosine-specific protein kinase which is associated with the plasma membrane of infected cells. Myristic acid is bound in an amide linkage to glycine 2 of p60src. Of the N-terminal 30 kilodaltons of p60src, only amino acids 1-14 are required for myristylation, and myristylation of p60src may be required for its membrane association, and for cell transformation. To test the hypothesis that the first 14 amino acids of p60src contain a recognition sequence for myristylation, we have fused the DNA sequence coding for these amino acids to either the fps gene of the F36 derivative of Fujinami sarcoma virus (FSV), or to the chimpanzee alpha-globin gene. We report here that although the fusion proteins were myristylated, the parental proteins were not, and unlike the non-myristylated F36 p91fps which was not bound to the plasma membrane, the myristylated fusion protein was bound, like p60src. We conclude that the first 14 amino acids of p60src contain a sequence which is sufficient for myristylation, and which may direct proteins to the plasma membrane.

Related
Resources

PMID: 3920530 [PubMed - indexed for MEDLINE]

Display

Abstract

Show: 20

Sort

Send to


Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimers](#)



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	▼ for						Go	Clear
Limits Preview/Index History Clipboard Details								

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

1: J Biol Chem 1994 Jul 29;269(30):19203-6

[Related Articles](#), [Links](#)

Entrez PubMed

The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.

PubMed
Services

Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, Brenner DA, Der CJ.

Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599.

Related
Resources

Recently developed CAAX peptidomimetic compounds have been shown to be potent and specific inhibitors of farnesyl protein transferase activity and to block the growth of Ras-transformed cells. However, whether this growth inhibitory action is specifically a consequence of blocking oncogenic Ras signaling has not been determined. To address this question, we have utilized mutants of the normally farnesylated oncogenic Ras protein (Ras-F) that are modified by alternative lipids, a geranylgeranyl isoprenoid (Ras-GG) or the fatty acid myristate (Myr-Ras), to determine the specificity of the CAAX peptidomimetic compound, B581. Like Ras-F, both Ras-GG and Myr-Ras are membrane-associated and transforming. Unexpectedly, NIH 3T3 cells transformed by each of the three Ras mutants underwent morphological alteration to a less transformed, but not normal, morphology. However, B581 inhibited the ability of only Ras-F-transformed cells, but not Ras-GG- or Myr-Ras- (or Raf-) transformed cells, to grow in soft agar. Furthermore, although all three lipid-modified versions of Ras stimulated mitogen-activated protein kinase activation, and both Jun and Elk-1 transcriptional activity, B581 inhibited only farnesylated Ras activation of these three downstream components of Ras signaling. Therefore, B581 prevents the growth of Ras-transformed cells by specifically antagonizing Ras-mediated signaling.

PMID: 8034681 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	▼	▼	Send to	▼
---------	----------	---	---	---	---------	---

[Write to the Help Desk](#)
NCBI NLM NIH

